A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews · 2026
Read A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours by Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13421006.txt.
Description
Yin Cheong Wong and colleagues model dosing for ginisortamab, an antibody drug for solid tumours. Their dose-finding study from twenty twenty-six uses data from an early clinical trial. The drug binds gremlin-1 and restores a growth control signal. Choosing the right dose matters for the next trial stages.
Blood data came from patients receiving the drug every two weeks. Doses spanned a wide range from low to high. A two-compartment model described how the drug spreads and clears. Exposure rose in step with dose across that range. Binding to gremlin-1 in blood was also captured well. Body surface area affected how the drug distributed. Simulations from the model now guide dose selection.
Catalog record
| CREATOR | Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |